Reference
Harrington AR, et al. Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation. Stroke : 2 Apr 2013. Available from: URL: http://dx.doi.org/10.1161/STROKEAHA.111.000402
Rights and permissions
About this article
Cite this article
Apixaban good value for money for stroke prevention in AF. PharmacoEcon Outcomes News 676, 4 (2013). https://doi.org/10.1007/s40274-013-0312-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0312-y